Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenming Chen

Showing results (191-200 of 228) with videos related to

Pageof 23
Sort By:
Analytical Chemistry|December 6, 2019
Endogenous Cys-Assisted GSH@AgNCs-rGO Nanoprobe for Real-Time Monitoring of Dynamic Change in GSH Levels Regulated by Natural DrugYan Qin, Jialong Fan, Wei Yang, et al.
Leukemia & Lymphoma|February 3, 2018
Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshopDaryl Tan, Jae Hoon Lee, Wenming Chen, et al.
Cancer Medicine|May 28, 2026
Clinical Characteristics, Treatment Patterns, and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Study From ChinaWenjing Li, Weiwei Tian, Jie Ma, et al.
Journal of Medicinal Chemistry|March 4, 2015
Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitorsXianfeng Lin, Wenming Chen, Zongxing Qiu, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2025
Perspectives on Anti-BCMA Bispecific Antibodies use in Multiple Myeloma-Experience from Asian CountriesCinnie Soekojo, Shimin Jasmine Chung, Ming-Tao Tsai, et al.
Blood Advances|October 29, 2025
Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple MyelomaChengcheng Fu, Wenming Chen, Zhen Cai, et al.
Clinical Hematology International|April 24, 2025
Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working GroupWenming Chen, Zhen Cai, James Cs Chim, et al.
Cancer Medicine|April 30, 2024
Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort studyAijun Liu, Hong Yu, Rui Hou, et al.
Annals of Hematology|July 29, 2024
Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort studyJingjing Deng, Xiaoqi Qin, Guangyu Ma, et al.
International Journal of Hematology|January 3, 2021
A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in ChinaJuan Du, Baijun Fang, Jian Li, et al.
Pageof 23

Showing results (191-200 of 228) with videos related to

Sort By:
Pageof 23
Analytical Chemistry|December 6, 2019
Endogenous Cys-Assisted GSH@AgNCs-rGO Nanoprobe for Real-Time Monitoring of Dynamic Change in GSH Levels Regulated by Natural DrugYan Qin, Jialong Fan, Wei Yang, et al.
Leukemia & Lymphoma|February 3, 2018
Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshopDaryl Tan, Jae Hoon Lee, Wenming Chen, et al.
Cancer Medicine|May 28, 2026
Clinical Characteristics, Treatment Patterns, and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Study From ChinaWenjing Li, Weiwei Tian, Jie Ma, et al.
Journal of Medicinal Chemistry|March 4, 2015
Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitorsXianfeng Lin, Wenming Chen, Zongxing Qiu, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2025
Perspectives on Anti-BCMA Bispecific Antibodies use in Multiple Myeloma-Experience from Asian CountriesCinnie Soekojo, Shimin Jasmine Chung, Ming-Tao Tsai, et al.
Blood Advances|October 29, 2025
Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple MyelomaChengcheng Fu, Wenming Chen, Zhen Cai, et al.
Clinical Hematology International|April 24, 2025
Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working GroupWenming Chen, Zhen Cai, James Cs Chim, et al.
Cancer Medicine|April 30, 2024
Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort studyAijun Liu, Hong Yu, Rui Hou, et al.
Annals of Hematology|July 29, 2024
Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort studyJingjing Deng, Xiaoqi Qin, Guangyu Ma, et al.
International Journal of Hematology|January 3, 2021
A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in ChinaJuan Du, Baijun Fang, Jian Li, et al.
Pageof 23